These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29548791)

  • 21. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
    Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
    Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
    Hotta C; Ogawa T; Shirasawa H
    Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of an aluminum salt-adjuvanted protein D-conjugated pneumococcal vaccine after exposure to subzero temperatures.
    Fortpied J; Wauters F; Rochart C; Hermand P; Hoet B; Moniotte N; Vojtek I
    Hum Vaccin Immunother; 2018 May; 14(5):1243-1250. PubMed ID: 29337646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.
    Sáez-Llorens X; Chan M; DeAntonio R; Petersen T; Olesen C; Jensen JS; Sørensen C; Ekstrand LM; Czort MK; Kristensen HH; Thulstrup N; Christoffersen DB
    Vaccine; 2022 Sep; 40(40):5835-5841. PubMed ID: 36064670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.
    Kouiavskaia D; Mirochnitchenko O; Dragunsky E; Kochba E; Levin Y; Troy S; Chumakov K
    J Infect Dis; 2015 May; 211(9):1447-50. PubMed ID: 25391313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.
    Dawson ED; Taylor AW; Johnson JE; Hu T; McCormick C; Thomas KN; Gao RY; Wahid R; Mahmood K; Rowlen KL
    J Immunol Methods; 2022 May; 504():113259. PubMed ID: 35314144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine].
    Lu L; Li XM; Liu DL; Zhang HR; Zhang ZJ; Wang HH; Liu F; Ning ZQ; Zhang LW; Chu P; Xie YT; Xu Y; Li J; Pang XH; Deng Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):510-3. PubMed ID: 22943896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative delivery of a thermostable inactivated polio vaccine.
    Kraan H; Ploemen I; van de Wijdeven G; Que I; Löwik C; Kersten G; Amorij JP
    Vaccine; 2015 Apr; 33(17):2030-7. PubMed ID: 25772676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mucosal adjuvant for the inactivated poliovirus vaccine.
    Steil BP; Jorquera P; Westdijk J; Bakker WA; Johnston RE; Barro M
    Vaccine; 2014 Jan; 32(5):558-63. PubMed ID: 24333345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array.
    Wan Y; Hickey JM; Bird C; Witham K; Fahey P; Forster A; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Jun; 107(6):1540-1551. PubMed ID: 29421219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
    Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
    J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase Ⅱ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine.
    Tang R; Li G; Zhang C; Zhi H; Zhu J; Wang J; Liang Q; Hu Y; Li C
    Hum Vaccin Immunother; 2020 Nov; 16(11):2641-2648. PubMed ID: 32347778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.
    Singer C; Knauert F; Bushar G; Klutch M; Lundquist R; Quinnan GV
    J Biol Stand; 1989 Apr; 17(2):137-50. PubMed ID: 2541133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
    Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
    Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of thermostable lyophilized inactivated polio vaccine.
    Kraan H; van Herpen P; Kersten G; Amorij JP
    Pharm Res; 2014 Oct; 31(10):2618-29. PubMed ID: 24760448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.